百奧賽圖-B(02315.HK)與SOTIO達成多靶點抗體合作協議
格隆匯7月16日丨百奧賽圖-B(02315.HK)公吿,公司與SOTIO Biotech已於今日達成一項研究合作和獨家選擇權及許可協議,據此,SOTIO獲授予選擇權來獲得利用百奧賽圖專有的RenLite平台產生的多種全人源雙特異性抗體的許可,而SOTIO將利用這些抗體進行靶向實體瘤的下一代抗體偶聯藥物(ADCs)開發。協議還包括允許SOTIO使用百奧賽圖專有ADC平台的一項選擇權。根據協議條款,百奧賽圖有權獲得首付款和潛在的里程碑付款高達3.255億美元,以及基於淨銷售額的低個位數百分比特許權使用費。SOTIO和百奧賽圖將在雙特異性項目研究階段緊密合作,SOTIO將負責ADC產品的非臨牀和臨牀開發、生產及商業化。
SOTIO正在通過將令人信服的科學轉化為患者利益來塑造靶向癌症療法的未來。SOTIO的產品管線包括三個臨牀階段的項目:SOT102,下一代靶向Claudin-18.2的抗體偶聯藥物;BOXR1030,一種靶向GPC3表達的腫瘤的代謝增強型CAR-T細胞療法;SOT201,下一代靶向PD-1的免疫細胞因子。SOTIO是PPF集團的成員公司。SOTIO是SOTIO Biotech a.s.在部分國家的註冊商標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.